Put Ro Sparks in its own comparison column. It describes a fixed 55 mg sildenafil / 22 mg tadalafil sublingual preparation, rather than every treatment sold by Ro. A useful comparison keeps the medicine, the supply and the payment interval together. Otherwise a cheaper-looking figure may describe a different formula or a larger commitment.
Availability: Public product listing; individual eligibility and current prescription require confirmation.
The exact product
The first comparison field is the actual preparation. The material distinction here is two PDE5 inhibitors in one prescription. Match every active ingredient and dosage form before looking at timing or unit cost. Products with similar names can contain different drugs; products with the same drug can use different formulations. Neither resemblance establishes interchangeability. The identity table is a record of the provider's listing, not a prescription-selection tool.
| Provider | Ro |
|---|---|
| Listed active ingredients | Sildenafil + tadalafil |
| Dosage form | Compounded sublingual drop |
| Regulatory distinction | Compounded preparation; the finished product is not FDA-approved. |
| Source basis | Ro: ED product catalog and plan quantities · Ro: medication pricing · Ro: Sparks product details |
Price, supply and payment
The quoted public price is $48 / 4 doses monthly. Treat the details below as the boundaries of that quote. Only calculate a unit figure when both the charge and the supplied quantity belong to the same offer; only calculate a monthly equivalent when the payment term is known. A blank quantity or renewal price should remain blank. Comparing invented complete totals is less reliable than explaining why two published offers cannot yet be matched.
| Monthly quantities | 4, 6, 8 or 10 allocated doses |
|---|---|
| Monthly charges | $48, $72, $96 or $120 respectively |
| Unit arithmetic | $12 per allocated dose; not a prescribed frequency |
| Timing limitation | Advertised onset is measured after dissolution, not necessarily from placement in the mouth |
What the research can support
Evidence is another comparison field, not a bonus point for a more complicated formula. This product's relevant evidence includes a 180-man trial of daily tadalafil plus as-needed sildenafil, not the Sparks sublingual formula. The missing comparison concerns controlled finished-product onset and comparative safety. A valid superiority claim would need a suitable comparator and outcome, not merely different marketing language. Record whether the source measured erection outcomes, subjective preference, absorption or something else before treating a percentage or timing claim as comparable.
| Evidence boundary | a 180-man trial of daily tadalafil plus as-needed sildenafil, not the Sparks sublingual formula |
|---|---|
| Not established here | controlled finished-product onset and comparative safety |
| Clinical and regulatory references | EAU: Management of erectile dysfunction · Cui et al. (2015): daily tadalafil with as-needed sildenafil · MedlinePlus: Tadalafil · DailyMed: Tadalafil prescribing information, including section 5.11 · FDA: Compounding and the FDA — questions and answers · MedlinePlus: Sildenafil |
Safety questions for the prescriber
Cost matching does not establish clinical suitability. A clinician must review nitrates, recreational nitrites, riociguat, other ED drugs, blood-pressure treatment and relevant medical history before prescribing. Do not try to recreate Ro Sparks with cheaper separate medicines. A do-it-yourself combination can create a new exposure without reproducing the studied or prescribed preparation. The specific safety distinction below can change which comparisons are meaningful for an individual.
| Multiple PDE5 inhibitors | Standard tadalafil labeling advises against combining PDE5 inhibitors; individualized rationale and monitoring are needed. |
|---|
Availability and the actual prescription
There is little value in ranking a price for an offer you cannot select. Our access finding is: Public product listing; individual eligibility and current prescription require confirmation. Account restrictions and a medical eligibility decision are different filters. Obtain confirmation of the exact current product before comparing cancellation rules or moving away from an existing plan. A product page that remains reachable is evidence of public documentation, not a guarantee of inventory or enrollment.
Refills, changes and cancellation
Add a change-of-treatment row to the budget. Ask whether a new formula requires another assessment, a replacement supply or a separate charge, and whether the current order can still be stopped. For the clinical side, use “Why is this combination appropriate after reviewing my response to a single medicine?” The two answers should come from the appropriate teams. A support agent's billing explanation does not settle medication safety, and a clinical message does not necessarily stop automatic processing.
| Order cancellation | Contact support promptly during processing; shipped orders cannot be canceled or returned. |
|---|---|
| Prescription refunds | Generally final; dispensing errors and rejected treatment requests are separate cases. |
| Renewal notice | Use the cutoff disclosed for the selected subscription; no universal ED deadline was verified. |
| Clinical change | The support article states a response within two business days; not independently measured. |
| Policy sources | Ro: terms of use, payments and subscriptions · Ro Support: canceling an order · Ro Support: return and refund policy |
Compare named products
The alternatives below are selected because they share an ingredient, format or clinical question. They are not ranked by efficacy. Compare them using the same columns: complete ingredients, supplied form, prescribed schedule, quantity, amount due and renewal. If one column remains unknown, identify that limitation in the comparison rather than awarding the offer a value advantage based on a starting banner.
Questions to keep with the offer
The decision-ready comparison is a written quote plus a prescribing explanation. The public records for Ro Sparks can narrow the questions but cannot provide those personal answers. No test purchase, clinical trial or pharmacy inspection was performed for this review. Sources identify advertised facts and evidence limits; commercial presentation elsewhere on this publication is not a clinical score.
| Ask about this formula | Why is this combination appropriate after reviewing my response to a single medicine? |
|---|---|
| Ask about the payment | What are the exact quantity, total due now, renewal amount and notice deadline? |
| Ask about a change | Who confirms the medical instructions, pharmacy order and next account charge? |
When to get urgent help
An erection lasting more than four hours or chest pain requires emergency care. Tell the treating clinician what was taken and when.
Sudden hearing or vision loss needs prompt medical attention. Do not wait for an ordinary account-support reply.
Back to all individual product reviews
Check the source
Public pages checked October 7, 2026. Provider material establishes advertised terms, not independently verified clinical results.
- Ro: ED product catalog and plan quantitiesProvider catalog; individual products, strengths and plan prices
- Ro: terms of use, payments and subscriptionsProvider policy; distinguish general subscription terms from Ro Body terms
- Ro Support: canceling an orderProvider support; processing orders and future shipments
- Ro Support: return and refund policyProvider support; prescription return and refund restrictions
- Ro Support: changing your prescriptionProvider support; clinical changes and follow-up
- EAU: Management of erectile dysfunctionSpecialty guideline; clinical evaluation, treatment, and limited combination evidence
- Cui et al. (2015): daily tadalafil with as-needed sildenafilPrimary clinical study; 180 patients, specific regimen, abstract reviewed via NCBI
- Ro: medication pricingProvider source; advertised plan prices and quantities
- Ro: Sparks product detailsProvider source; compounded formula, subscription pricing, and care process
- NIDDK: Diagnosis of erectile dysfunctionGovernment patient information
- MedlinePlus: TadalafilDrug information; standard tadalafil products
- DailyMed: Tadalafil prescribing information, including section 5.11Prescribing label; not evidence for the 4Play combination
- FDA: Compounding and the FDA — questions and answersGovernment guidance on compounded medications
- MedlinePlus: SildenafilDrug information; standard sildenafil products